Protagonist Therapeutics IncPTGX
ASignal's systematic analysis rates PTGX as Neutral.
Reflects the latest available analysis · analyzed Aug 30, 2026
The case on PTGX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (37.49% YoY)
- Exceptional gross margin (100.00%)
- High operating margin (74.37%)
- Strong financial health (Debt/Equity: 0.01x)
- High cash position ($782.58M)
- Current ratio of 21.71x indicates strong liquidity
- Overvalued based on high P/E (144.33x) and forward P/E (2434.72x)
- Negative price momentum (-0.09)
- MACD below signal line indicating weakening momentum
- High valuation multiples (P/S: 33.12x, EV/Revenue: 30.38x)
- No Reddit mentions suggesting limited retail interest
See the full verdict on PTGX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PTGX
Most investors never get a second opinion, let alone several. ASignal runs PTGX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.